This educational activity is directed toward internists and internal medicine subspecialists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in lipid management will be invited to participate, as well.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease inhibitors provide important advances in the management of dyslipidemia and cardiovascular disease risk. Clinician education about current and emerging data for this class of agents is expected to improve clinical care and patient outcomes. This activity will help clinicians to identify specific subsets of patients who may be candidates for nonstatin-based approaches, including optimized application of PCSK9 inhibitors. It will also review data concerning these agents and best practices for their clinical use.
Upon completion of this activity, participants should be better able to: